Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gen-Probe launches colon cancer mutation test kit in Europe

This article was originally published in Clinica

Executive Summary

Gen-Probe has launched its Elucigene KRAS.BRAF kit in Europe. The assay is designed to help tailor treatment for colorectal cancer patients, by detecting seven common mutations in the KRAS gene and the V600E mutation in the BRAF gene. Patients with mutations in these genes do not respond to EGFR inhibitor drugs such as Amgen's Vectibix. Elucigene KRAS.BRAF is a single-tube, PCR-based fluorescent assay designed for simplicity and ease of use. It reduces laboratory workload, analysis time and the potential for sample mix-up, San Diego, California-based Gen-Probe claims. The test is not yet cleared in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096031

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel